BACKGROUND: Group patient visits are medical appointments shared among patients with a common medical condition. This care delivery method has demonstrated benefits for individuals with chronic conditions but has not been evaluated for Parkinson disease (PD). METHODS: We conducted a 12-month, randomized trial of group patient visits vs usual (one-on-one) care for patients with PD. Visits were led by one of 3 study physicians, included patients and caregivers, and lasted approximately 90 minutes. Those receiving group visits had 4 sessions over 12 months. The primary outcome measure was feasibility as measured by the ability to recruit participants and by the proportion of participants who completed the study. The primary efficacy outcome was quality of life as measured by the PD Questionnaire-39. RESULTS:Thirty patients and 27 caregivers enrolled in the study. Thirteen of the 15 patients randomized to group patient visits and 14 of the 15 randomized to usual care completed the study. Quality of life measured 12 months after baseline between the 2 groups was not different (25.9 points for group patient visits vs 26.0 points for usual care; p = 0.99). CONCLUSIONS: Group patient visits may be a feasible means of providing care to individuals with PD and may offer an alternative or complementary method of care delivery for some patients and physicians. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that group patient visits did not improve quality of life for individuals with PD over a 1-year period.
RCT Entities:
BACKGROUND: Group patient visits are medical appointments shared among patients with a common medical condition. This care delivery method has demonstrated benefits for individuals with chronic conditions but has not been evaluated for Parkinson disease (PD). METHODS: We conducted a 12-month, randomized trial of group patient visits vs usual (one-on-one) care for patients with PD. Visits were led by one of 3 study physicians, included patients and caregivers, and lasted approximately 90 minutes. Those receiving group visits had 4 sessions over 12 months. The primary outcome measure was feasibility as measured by the ability to recruit participants and by the proportion of participants who completed the study. The primary efficacy outcome was quality of life as measured by the PD Questionnaire-39. RESULTS: Thirty patients and 27 caregivers enrolled in the study. Thirteen of the 15 patients randomized to group patient visits and 14 of the 15 randomized to usual care completed the study. Quality of life measured 12 months after baseline between the 2 groups was not different (25.9 points for group patient visits vs 26.0 points for usual care; p = 0.99). CONCLUSIONS: Group patient visits may be a feasible means of providing care to individuals with PD and may offer an alternative or complementary method of care delivery for some patients and physicians. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that group patient visits did not improve quality of life for individuals with PD over a 1-year period.
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: Mary Lessig; Jeanette Farrell; Ernest Madhavan; Christopher Famy; Brian Vath; Teresa Holder; Soo Borson Journal: J Am Geriatr Soc Date: 2006-12 Impact factor: 5.562
Authors: E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner Journal: Neurology Date: 2006-11-02 Impact factor: 9.910
Authors: E Ray Dorsey; Vinayak Venkataraman; Matthew J Grana; Michael T Bull; Benjamin P George; Cynthia M Boyd; Christopher A Beck; Balaraman Rajan; Abraham Seidmann; Kevin M Biglan Journal: JAMA Neurol Date: 2013-05 Impact factor: 18.302
Authors: Ronald A Remick; Yuriko Araki; Robin Bruce; Chris Gorman; Judy Allen; Abigail K Remick; Scott A Lear Journal: Can J Psychiatry Date: 2014-04 Impact factor: 4.356
Authors: Susan R Kirsh; David C Aron; Kimberly D Johnson; Laura E Santurri; Lauren D Stevenson; Katherine R Jones; Justin Jagosh Journal: BMC Health Serv Res Date: 2017-02-04 Impact factor: 2.655